留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

0.05%阿托品滴眼液对小学生近视控制的有效性和安全性

朱勤 周圆 张晓帆 张洁莹 胡敏

朱勤, 周圆, 张晓帆, 张洁莹, 胡敏. 0.05%阿托品滴眼液对小学生近视控制的有效性和安全性[J]. 中国学校卫生, 2021, 42(2): 170-172, 176. doi: 10.16835/j.cnki.1000-9817.2021.02.003
引用本文: 朱勤, 周圆, 张晓帆, 张洁莹, 胡敏. 0.05%阿托品滴眼液对小学生近视控制的有效性和安全性[J]. 中国学校卫生, 2021, 42(2): 170-172, 176. doi: 10.16835/j.cnki.1000-9817.2021.02.003
ZHU Qin, ZHOU Yuan, ZHANG Xiaofan, ZHANG Jieying, HU Min. Efficacy and safety of 0.05% atropine eye drops for retarding myopia progression in Chinese primary school students[J]. CHINESE JOURNAL OF SCHOOL HEALTH, 2021, 42(2): 170-172, 176. doi: 10.16835/j.cnki.1000-9817.2021.02.003
Citation: ZHU Qin, ZHOU Yuan, ZHANG Xiaofan, ZHANG Jieying, HU Min. Efficacy and safety of 0.05% atropine eye drops for retarding myopia progression in Chinese primary school students[J]. CHINESE JOURNAL OF SCHOOL HEALTH, 2021, 42(2): 170-172, 176. doi: 10.16835/j.cnki.1000-9817.2021.02.003

0.05%阿托品滴眼液对小学生近视控制的有效性和安全性

doi: 10.16835/j.cnki.1000-9817.2021.02.003
基金项目: 

国家自然科学基金资助项目 81560168

云南省第二人民医院院内课题 ynkt2019005

详细信息
    作者简介:

    朱勤(1985-),女,云南人,硕士,主治医师,主要研究方向为儿童眼病及眼视光

    通讯作者:

    胡敏, E-mail:fudanhumin@sina.com

  • 中图分类号: R  179  R  778.11

Efficacy and safety of 0.05% atropine eye drops for retarding myopia progression in Chinese primary school students

  • 摘要:   目的  评估0.05%阿托品滴眼液对小学生近视控制的有效性和安全性,为制定近视的相关防控措施提供参考依据。  方法  选取2016年1月至2019年1月云南省第二人民医院儿童眼科门诊收治的8~12岁近视小学生共计188例,随机均分为实验组(93例)和对照组(95例)。在第1~24个月,阿托品组儿童每晚睡前双眼滴1次0.05%阿托品滴眼液。对照组儿童每晚睡前双眼滴1次0.3%玻璃酸钠滴眼液。第25~36个月,实验组及对照组儿童均停止用药。在随访期内,每组儿童均在用药前、用药后每6个月检查其等效球镜度、眼轴长度、眼压变化,问卷调查药物相关不良反应发生率。  结果  在用药期间,实验组等效球镜度年进展值[(-0.35±0.21)D/年]及眼轴长度年进展值[(0.11±0.07)mm/年]明显少于对照组[(-0.83±0.26)D/年,(0.37±0.22)mm/年](t值分别为1.29,-1.37,P值均 < 0.05)。停用阿托品滴眼液后,实验组的等效球镜进展值[(-0.40±0.29)D/年]及眼轴长度进展值[(0.10±0.04)mm/年]明显低于对照组[(0.73±0.40)D/年,(0.30±0.11)mm/年]。在整个随访期间,没有发现与阿托品相关的严重不良事件。停用阿托品后,瞳孔大小、近视力和调节幅度逐渐恢复到治疗前水平。  结论  局部使用0.05%阿托品滴眼液可有效延缓青少年近视进展,且不导致眼压异常及严重不良反应,具有较好的应用安全性。
  • 表  1  实验组及对照组小学生治疗前后等效球镜值比较(x ±s,D/年)

    Table  1.   Comparison of spherical equivalent over time in treatment group and control group (x ±s, D/year)

    组别 眼数 治疗前 治疗后 年均增长值
    6个月 12个月 18个月 24个月 30个月 36个月
    实验组 186 -3.29±0.22 -3.39±0.29 -3.52±0.71 -3.70±0.61 -3.83±1.01 -4.08±0.95 -4.23±1.03 -0.31±0.21
    对照组 190 -3.32±0.52 -3.73±0.81 -4.18±0.66 -4.64±0.72 -5.09±1.16 -5.45±1.16 -5.82±1.16 -0.83±0.26
    t 1.01 0.29 3.87 4.52 4.29 5.00 5.02 1.29
    P 0.31 0.03 0.02 0.02 0.01 0.01 0.01 0.01
    下载: 导出CSV

    表  2  治疗前后实验组及对照组小学生眼轴长度值比较(x ±s,mm/年)

    Table  2.   Comparison of changes in axial length over time in treatment group and control group (x ±s, mm/year)

    组别 眼数 治疗前 治疗后 年均增长值
    6个月 12个月 18个月 24个月 30个月 36个月
    治疗组 186 23.75±0.22 23.80±0.19 23.87±0.12 23.91±0.17 23.99±0.23 24.05±0.13 24.09±0.23 0.11±0.07
    对照组 190 23.68±0.19 23.81±0.11 24.19±0.08 24.31±0.15 24.50±0.18 24.69±0.16 24.80±0.21 0.37±0.22
    t 1.27 -0.98 -1.16 -2.94 -3.65 -3.50 -5.29 -1.37
    P 0.29 0.16 0.03 0.02 0.01 0.01 0.00 0.00
    下载: 导出CSV
  • [1] CHEN M, WU A M, ZHANG L N, et al. The increasing prevalence of myopia and high myopia among high school students in Fenghua city, eastern China: a 15-year population-based survey[J]. BMC Ophthalmol, 2018, 159, DOI: 10.1186/s12886-018-0829-8(2018).
    [2] HOLDEN B A, FRICKE T R, WILSON D A, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050[J]. Ophthalmology, 2016, 123(5): 1036-42. DOI: 10.1016/j.ophtha.2016.01.006.
    [3] LV L, ZHANG Z. Pattern of myopia progression in Chinese medical students: a two-year follow-up study[J]. Graefes Arch Clin Exp Ophthalmol, 2013, 251(1): 163-168. doi: 10.1007/s00417-012-2074-9
    [4] SUN J, ZHOU J, ZHAO P, et al. High prevalence of myopia and high myopia in 5060 Chinese university students in Shanghai[J]. Invest Ophthalmol Vis Sci, 2012, 53(12): 7504-7509. doi: 10.1167/iovs.11-8343
    [5] CHIA A, CHUA W H, CHEUNG Y B, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses(Atropine for the Treatment of Myopia 2)[J]. Ophthalmology, 2012, 119(2): 347-354. doi: 10.1016/j.ophtha.2011.07.031
    [6] CHUA W H, BALAKRISHNAN V, CHAN Y H, et al. Atropine for the treatment of childhood myopia[J]. Ophthalmology, 2006, 13(1): 2285-2291. http://www.sciencedirect.com/science/article/pii/S0161642006007597
    [7] CHIA A, LU Q S, TAN D. Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eye drops[J]. Ophthalmology, 2016, 123(2): 391-399. doi: 10.1016/j.ophtha.2015.07.004
    [8] YAM J C, JIANG Y, TANG S M, et al. Low-Concentration atropine for myopia progression(LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control[J]. Ophthalmology, 2019, 126(1): 113-124. doi: 10.1016/j.ophtha.2018.05.029
    [9] WU P C, YANG Y H, FANG P C. The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren[J]. J Ocul Pharmacol Ther, 2011, 27(5): 461-466. doi: 10.1089/jop.2011.0027
    [10] PINELES S L, KRAKER R T, VANDERVEEN D K, et al. Atropine for the prevention of myopia progression in children: a report by the American academy of ophthalmology[J]. Ophthalmology, 2017, 124(12): e1857-e1866. doi: 10.1016/j.ophtha.2017.05.032
    [11] KUMARAN A, HTOON H M, TAN D, et al. Analysis of changes in refraction and biometry of atropine-and placebo-treated eyes[J]. Invest Ophthalmol Vis Sci, 2015, 56(9): e5650-e5655. doi: 10.1167/iovs.14-14716
    [12] TIGGES M, IUVONE P M, FERNANDES A, et al. Effects of muscarinic cholinergic receptor antagonists on postnatal eye growth of Rhesus monkeys[J]. Optom Vis Sci, 1999, 76(6): e397-e407. doi: 10.1097/00006324-199906000-00020
    [13] QU J, ZHOU X, XIE R, et al. The presence of M1 to M5 receptors in human sclera: evidence of the sclera as a potential site of action for muscarinic receptor antagonists[J]. Curr Eye Res, 2006, 31(7/8): e587-e597. http://europepmc.org/abstract/MED/16877267
    [14] TAN D, TAY S A, LOH K L, et al. Topical atropine in the control of myopia[J]. Asia Pac J Ophthalmol(Phila), 2016, 5(6): e424-e428. doi: 10.1097/APO.0000000000000232
    [15] PREPAS S B. Light, literacy and the absence of ultraviolet radiation in the development of myopia[J]. Med Hypotheses, 2008, 70(3): e635-e637. doi: 10.1016/j.mehy.2007.07.023
    [16] LIN H J, WEI C C, CHANG C Y, et al. Role of chronic inflammation in myopia progression: clinical evidence and experimental validation[J]. Ebio Med, 2016, 10: e269-e281. DOI: 10.1016/j.ebiom.2016.07.021.
  • 加载中
表(2)
计量
  • 文章访问数:  593
  • HTML全文浏览量:  173
  • PDF下载量:  37
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-05-24
  • 修回日期:  2020-07-13
  • 网络出版日期:  2021-04-06
  • 刊出日期:  2021-02-25

目录

    /

    返回文章
    返回